Table 3 Influence of vaccination on behaviors in GK decision during the pandemic period
No (n = 185) | Yes (n = 148) | p value | |||
|---|---|---|---|---|---|
Mean | ± SD | Mean | ± SD | ||
Age (years) | 56.4 | ± 14.9 | 56.6 | ± 15.0 | 0.958 |
Sex-Male (n, %) | 89 | (48.1%) | 47 | (31.7%) | 0.004 |
Neurological deficits (n,%) | 121 | (65.4%) | 86 | (58.1%) | 0.211 |
Malignance (n,%) | 64 | (34.6%) | 49 | (33.1%) | 0.866 |
Total TV (cc) (n = 538) | 40.6 | ± 507.9 | 3.7 | ± 4.6 | 0.318 |
Peripheral dose (GY) | 16.1 | ± 5.9 | 15.8 | ± 5.7 | 0.086 |
Number of lesions | 1.5 | ± 1.3 | 1.4 | ± 1.1 | 0.506 |
KPS | 83.9 | ± 7.3 | 84.7 | ± 8.4 | 0.287 |
ECOG | 0.7 | ± 0.7 | 0.7 | ± 0.7 | 0.377 |
Charlson comorbidity index | 4.6 | ± 3.2 | 3.1 | ± 3.1 | < 0.001 |
Time from diagnosis to GK treatment (days) | 54.5 | ± 27.6 | 29.6 | ± 10.9 | < 0.001 |
Time from diagnosis to GK consultation (days) | 36.8 | ± 25.5 | 12.2 | ± 7.1 | < 0.001 |
Duration of GK treatment (hours) | 5.1 | ± 1.4 | 5.2 | ± 1.4 | 0.503 |
OPD frequency (time/year) | 6.9 | ± 6.0 | 10.0 | ± 6.3 | < 0.001 |
MRI frequency (time/year) | 1.0 | ± 1.0 | 2.3 | ± 1.0 | < 0.001 |